Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

antihistamine. For the primary endpoint, the omalizumab 75 mg dose group did not demonstrate statistical significance compared to placebo. However, omalizumab 150 mg and 300 mg dose groups met the pre-specified primary endpoint and all eight pre-specified secondary endpoints in the ASTERIA II trial, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy. Patient response, as measured by the median time to Minimally Important Difference (MID) in itch severity score,  a secondary endpoint, occurred at Week 1 (300 mg dose) and Week 2 (150 mg dose), compared to Week 4 in the placebo group.

The incidence and severity of adverse events (AEs) was similar across treatment groups. The most frequently reported treatment-emergent adverse events in patients taking omalizumab (>10% in any omalizumab treatment arm) in the study (including treatment period and follow-up period) were nasopharyngitis (nasal and throat infection or common cold), idiopathic urticaria (hives and itching, trigger unknown) and headache.  Five (6.3%) patients experienced serious adverse events (SAEs) in the omalizumab 300 mg dose group, compared to two (2.5%) in the placebo group. In the 150 mg and 75 mg dose groups, one patient experienced SAEs in each group (1.1% and 1.3%, respectively). No deaths were reported during this study.

About Omalizumab
Omalizumab is not indicated for CIU.

Omalizumab is a biologic therapy unique in targeting immunoglobulin E (IgE). Research is ongoing to understand the mechanism of action of omalizumab in CIU and to investigate its potential impact on the drivers of CIU. Omalizumab is approved for the treatment of moderate to severe allergic asthma under the brand-name Xolair® in more than 90 countries, including the US since 2003 and the EU since 2005. In the US, Xolair is indicated for appropriate people who are
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Sarnova, parent ... launch of the new www.tri-anim.com website, ... specialty healthcare distributor of respiratory, anesthesia and other ... The site has many new ... experience, making online shopping and ordering easier and ...
(Date:3/2/2015)... , March 2, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... announced public offering of common stock have exercised their ... common stock at a price to the public of ... the offering is expected to be $64.8 million, after ...
(Date:3/2/2015)... FRANCISCO, Calif. , March 2, 2015 /PRNewswire/ ... the treatment of cancer, today announced the creation ... leading researchers and clinicians in the fields of ... The new advisory boards will provide guidance ... owned pipeline of precision immunotherapies and Probody drug ...
Breaking Medicine Technology:Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 2Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 3Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... spans paleogenomics, paired-end mapping, and ... gene expression ... a Roche,company, is the subject of three ground-breaking studies published ... Sequencer(TM),system. The studies, entitled "Paired-End Mapping Reveals Extensive Genomic,Structural Variation ...
... SOPHIA ANTIPOLIS, France, Oct. 2 NicOx ... promising clinical and,preclinical results from its collaboration ... Congress of Dermatology, in Buenos Aires, Argentina.,These ... a prototype compound, showing,the potential for improved ...
Cached Medicine Technology:Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 2Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 3Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 4NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 2NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 3
(Date:3/2/2015)... 02, 2015 ZoomCare announced today ... American healthcare. Zoom will expand its Portland on-demand ... and advanced care studios delivering urgent care, primary ... specialty care and outpatient surgery. With its new ... almost all healthcare needs outside of hospitalization. , ...
(Date:3/2/2015)... New York, New York (PRWEB) March 02, 2015 ... of Creative Recovery at Recovery Unplugged™—will be delivering ... You: A Singer/Songwriter's Perspective on the Art of ... on Addiction Disorders (NCAD) and Behavioral Healthcare Executive ... to his name, Mr. Supa’s songs have been ...
(Date:3/2/2015)... 02, 2015 This year, the National Multiple ... will provide opportunities for people across the country to unite, ... people with MS live their best lives. MS Awareness Week ... inspire others to join the Society’s vision of a world ... often disabling disease of the central nervous system, interrupts the ...
(Date:3/2/2015)... 2015 Regulatory Compliance Associates® Inc. ... regulatory and technical consulting, announces Mr. Seyed Khorashahi ... , Before joining RCA, Mr. Khorashahi had ... in all aspects of developing safety-critical medical devices. ... (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Many mainstream ... reported cases of measles. But how much of that ... vaccinated their toddlers to prevent measles, but whose youngsters ... educational lectures from 150 speakers comprised of professionals, clinicians, ... the recent news stories and questions about the body ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2
... In what’s being called a novel finding, researchers using ... women with sensory conversion disorder, better known as// hysteria. ... understanding hysteria, an unexplained neurological disorder in which a ... medically wrong with them. ,The study ...
... a report, San Mateo Seniors quarantine 3 more medical facilities ... more this year than the// past. ,San Mateo ... which has already sickened dozens of people in a Belmont ... The doctors added that the outbreak is being reported ...
... some of Britain's leading scientists have supported the use ... and reduce deaths// from disease. But only if no ... speaking on the use of primates, Lead author of ... cases primates are essential to answer scientific questions because ...
... hands in a chemical explosion some 19 years ago had double ... its kind done in Spain, and worldwide first on a woman. ... this ten- hour operation. ,The leading surgeon Pedro Cavadas ... hospital next week and should get back full use of her ...
... the wane and excellent coverage during recent pulse polio ... government that the next few pulse polio rounds must ... are not being sufficiently immunized early enough. The group ... advised the government on strategies on polio eradication. ...
... to identify the cause of allergy due to consuming peanuts//. ... will be made to have peanut extracts. ,Peanut allergy, one ... in the last decade. Presently, 70 school going kids are affected ... parents to avoid peanuts in the child’s diet might be one ...
Cached Medicine News:Health News:Quarantine Hits 3 More Hospitals In San Mateo 2Health News:Britain Scientists Support the Use of Primates in Research 2Health News:Polio Outbreak on Wane: Next Rounds Must Focus on Youngest Children 2
... 3800 and 3900/P pulse oximeters are ... proprietary clinical patient motion algorithm from ... performance:, ,The 3800 and 3900 ... environmental/ mechanical stress testing such as ...
... anesthesia monitor., ,The Cardiocap/5 is ... use in the operating room, ambulatory ... The Cardiocap/5 offers full vital signs ... oxygenation and circulation to advanced airway ...
... of clinical information. , ,S/5 Clinical ... connectivity solutions that help you and your ... care. You will have access to essential ... it with your care team and specialists, ...
... Releasing the power of clinical information. , ... generation of clinical connectivity solutions that help ... effective, high-quality patient care. You will have ... able to share it with your care ...
Medicine Products: